Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
This study has been completed.
Information provided by:
First received: May 22, 2006
Last updated: September 6, 2013
Last verified: September 2009
The primary objective is to assess the effect of re-treatment after relapse in subjects with moderate to severe chronic plaque psoriasis having responded to a first treatment.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||Efficacy and Safety of Re-treatment With Cimzia® at 2 Dose Regimens for 12 Weeks in Subject Suffering From Moderate to Severe Chronic Plaque Psoriasis Having Relapsed After Response to First Treatment|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by UCB, Inc.:
Primary Outcome Measures:
- To assess the efficacy of re-treatment with cimzia® compared to first treatment in patients having relapsed after response to first treatment.
Secondary Outcome Measures:
- To describe safety of re-treatment.
|Study Start Date:||April 2006|
|Study Completion Date:||May 2007|
|Primary Completion Date:||May 2007 (Final data collection date for primary outcome measure)|
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00329303
|Nice Cedex 3, France|
|Pierre Benite, France|
Sponsors and Collaborators
|Study Director:||UCB Clinical Trial Call Center||UCB, Inc.|